



HANDBOOK OF DIABETES

5TH EDITION

Rudy Bilous
Richard Donnelly
Iskandar Idris



WILEY Blackwell

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[Preface](#)

[Key to the boxes](#)

[List of abbreviations](#)

[Part 1: Introduction to diabetes](#)

[Chapter 1: Introduction to diabetes](#)

[Chapter 2: History of diabetes](#)

[Chapter 3: Diagnosis and classification of diabetes](#)

[Intermediate categories of hyperglycaemia:](#)

[Pre-diabetes](#)

[Classification of diabetes](#)

[Chapter 4: Public health aspects of diabetes](#)

[Primary prevention of Type 2 Diabetes](#)

[Providing access to structured diabetes education](#)

[Improving diabetes treatment and care](#)

[Commissioning diabetes services](#)

[Chapter 5: Normal physiology of insulin secretion and action, and the incretin effect](#)

[Islet structure and function](#)

[Insulin synthesis and insulin polypeptide structure](#)

[Insulin secretion](#)

[The incretin effect](#)

[Insulin receptor signalling](#)

[The family of GLUT transporters](#)

[Chapter 6: Epidemiology and aetiology of type 1 diabetes](#)

[Introduction](#)

[Epidemiology](#)

[Aetiology](#)

[Genetics](#)

[Environmental and maternal factors](#)

[Viruses](#)

[Apoptosis](#)

[Dietary factors](#)

[Toxins](#)

[Animal models](#)

[Hygiene hypothesis](#)

[Accelerator hypothesis](#)

[Chapter 7: Epidemiology and aetiology of type 2 diabetes](#)

[Prevalence rates and global burden](#)

[Urban versus rural](#)

[Impaired glucose tolerance](#)

[Incidence](#)

[Risk factors for type 2 diabetes](#)

[Conclusion](#)

[Chapter 8: Other types of diabetes](#)

[Introduction](#)

[Monogenic Diabetes and association with other Inherited Conditions](#)

[Other monogenic causes](#)

Pancreatic disease

Diabetes complicating other endocrine diseases

Medication associated diabetes

Part 2: Metabolic control and complications

Chapter 9: Diabetes control and its measurement

Introduction

Capillary blood glucose monitoring

Urine glucose monitoring

Glycated haemoglobin

IFCC standard

Estimated average glucose (eAG)

Glucose variability

Fructosamine

Urine and blood ketone measurements

Continuous glucose monitoring (CGM) systems

Chapter 10: Management of type 1 diabetes

Insulin replacement

Intensive insulin therapy

Diet and Carbohydrate counting

Glycaemic targets

Continuous subcutaneous insulin infusion

Chapter 11: Management of type 2 diabetes

Chapter 12: Diabetic ketoacidosis (DKA), hyperglycaemic hyperosmolar state (HHS) and lactic acidosis

Precipitating factors for diabetic ketoacidosis

Pathophysiology

Treatment

Complications of diabetic ketoacidosis

[Hyperosmolar hyperglycaemic state](#)

[Lactic acidosis](#)

[Chapter 13: Hypoglycaemia](#)

[Chapter 14: Causes of complications](#)

[Hyperglycaemia](#)

[Blood pressure](#)

[Metabolic memory](#)

[How does hyperglycaemia cause tissue complications?](#)

[Chapter 15: Diabetic eye disease](#)

[Pathology and clinical appearances](#)

[Factors associated with the development of retinopathy](#)

[Classification of retinopathy](#)

[Treatment of retinopathy](#)

[Surveillance and screening](#)

[Chapter 16: Diabetic nephropathy](#)

[Natural history](#)

[Stages of nephropathy](#)

[Epidemiology](#)

[Screening for nephropathy](#)

[Pathology and pathophysiology](#)

[Risk factors for nephropathy](#)

[Management](#)

[Is it diabetic nephropathy?](#)

[Chapter 17: Diabetic neuropathy](#)

[Chronic sensorimotor neuropathy](#)

[Chapter 18: Blood lipid abnormalities](#)

[Chapter 19: Hypertension in diabetes](#)

[Causative links](#)

[Definition of hypertension and targets](#)

[Diagnosis of hypertension](#)

[Management](#)

[Chapter 20: Macrovascular disease in diabetes](#)

[Atherosclerosis](#)

[Glycaemic vascular injury](#)

[Chapter 21: Foot problems in diabetes](#)

[Chapter 22: Sexual problems in diabetes](#)

[Chapter 23: Gastrointestinal problems in diabetes](#)

[Symptoms](#)

[Oesophagus](#)

[Gastroparesis](#)

[Small bowel](#)

[Large bowel](#)

[Abdominal pain](#)

[Gut microbiota](#)

[Chapter 24: Non-alcoholic liver disease \(NAFLD\)](#)

[Introduction](#)

[Definition](#)

[Risk factors for NAFLD](#)

[NAFLD and diabetes](#)

[Screening](#)

[Management](#)

[Thiazolidinediones](#)

[Glucagon-like peptide-1 analogs and DPP-4 inhibitors](#)

[Sodium Glucose cotransporter 2 inhibitors](#)

Vitamin E

Bariatric surgery

Statins

Chapter 25: Diabetes and cancer

Introduction

Epidemiology

Possible biological mechanisms

Effect of diabetes on cancer mortality and treatment

Effects of cancer therapy on diabetes

Effects of diabetes therapies on cancer incidence and progression

Chapter 26: Skin and connective tissue disorders in diabetes

Diabetic dermopathy

Necrobiosis lipoidica diabetorum

Acanthosis nigricans

Diabetic bullae

Granuloma annulare

Skin thickening, waxy skin, and stiff joints

Other skin conditions

Chapter 27: Psychological and psychiatric problems in diabetes

Depression and anxiety

Diabetes distress

Cognitive changes

Severe Mental Illness

Published guidance.

Part 3: The spectrum and organisation of diabetes care

Chapter 28: Intercurrent situations that affect diabetes control

Exercise

Drugs

Infections

Enteral feeding

Surgery and critical intercurrent illness

Chapter 29: Pregnancy and diabetes

Effects of pregnancy on the woman with diabetes

Effects of maternal diabetes on the pregnancy

Management of pregnancy in diabetes

Gestational diabetes

Contraception

Chapter 30: Diabetes in childhood and adolescence

Chapter 31: Diabetes in old age

Chapter 32: Diabetes and lifestyle

Introduction

Smoking

Alcohol

Drug and substance abuse

Driving

Employment

Travel and leisure activities.

Chapter 33: Organisation of diabetes care: integrating diabetes service

What is integrated diabetes care?

What are the essential components to an integrated diabetes service?

[Impact of COVID-19 pandemic: lessons on organizing diabetes care](#)

[Chapter 34: Transplantation and stem cell therapy](#)

[Pancreas transplantation](#)

[Islet cell transplantation](#)

[Xenotransplantation](#)

[Stem cell therapy](#)

[Gene therapy](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 3

[Table 3.1 Diagnostic criteria for Type 2 diabetes.](#)

[Table 3.2 Use of HbA1c >6.5% \(48 mmol/mol\) as a cut-off for making the diagnosis...](#)

[Table 3.3 Historically, HbA1c has been reported in percentage values describi...](#)

Chapter 4

[Table 4.1 Criteria that define structured patient education in the NICE guida...](#)

[Table 4.2 Transformation Funding in the UK in 2017 is targeting 4 key areas t...](#)

[Table 4.3 Top Tips For Commissioning Diabetes Services.](#)

Chapter 6

[Table 6.1 Highest global rates of incidence per annum of type 1 diabetes in c...](#)

[Table 6.2 Main non- HLA polymorphisms that have been used in predictive model...](#)

[Table 6.3 Associated foetal, maternal, dietary and environmental factors with...](#)

Chapter 7

[Table 7.1 Definition of metabolic syndrome.](#)

Chapter 8

[Table 8.1 Different genetic aetiologies of main types of MODY.](#)

Chapter 9

[Table 9.1 Available measures of glycaemic control and their main clinical use...](#)

[Table 9.2 Guide to values of HbA1c \(IFCC\) and DCCT \(NGSP\) standardised assay.](#)

[Table 9.3 Estimated average blood glucose concentration derived from HbA1c re...](#)

Chapter 10

[Table 10.1 Insulin preparations and their costs in the UK based upon the Brit...](#)

[Table 10.2 Pharmacological properties of the available intermediate and long...](#)

[Table 10.3 Glycaemic targets from NICE \(National Institute of Health Care Exc...](#)

[Table 10.4 Incidence of reported ketoacidosis and severe hypoglycaemia over 3...](#)

[Table 10.5 Achieved HbA1c on Multiple Daily Injections \(MDI\) or Continuous Su...](#)

Chapter 12

[Table 12.1 UK and US Diagnostic criteria for DKA and HHS.](#)

[Table 12.2 Precipitating causes of DKA.](#)

[Table 12.3 Water and electrolyte deficiencies in DKA and HHS.](#)

[Table 12.4 Causes of lactic acidosis.](#)

Chapter 13

[Table 13.1 Factors that precipitate or predispose to hypoglycaemia in patient...](#)

Chapter 14

[Table 14.1 Main features of the ACCORD \(Action to Control Cardiovascular Risk...](#)

Chapter 16

[Table 16.1 Definition of diabetic nephropathy by albuminuria and test specime...](#)

[Table 16.2 Stages of chronic kidney disease \(CKD\) and their mapping to histor...](#)

Chapter 17

[Table 17.1 Treatments for symptomatic diabetic polyneuropathy_pain-dosing_and...](#)

Chapter 19

[Table 19.1 Comparison of guidelines for diagnostic thresholds and treatment t...](#)

[Table 19.2 Stages of hypertension.](#)

[Table 19.3 Lifestyle changes and the magnitude of reported reduction in blood...](#)

[Table 19.4 RAS-blocking agents.](#)

[Table 19.5 Calcium channel-blocking agents.](#)

[Table 19.6 Diuretics.](#)

[Table 19.7 \$\beta\$ -Blockers.](#)

Chapter 21

[Table 21.1 NICE has recommended this risk stratification system with appropri...](#)

[Table 21.2 Wagner Ulcer Classification System.](#)

[Table 21.3 University of Texas Wound Classification System.](#)

Chapter 23

[Table 23.1 Prevalence of gastrointestinal symptoms in diabetes mellitus and c...](#)

[Table 23.2 Step-wise approach to the patient with suspected gastroparesis.](#)

[Table 23.3 A step-wise approach to the patient with suspected autonomic diarr...](#)

Chapter 25

[Table 25.1 List of cancers and the strength of their reported association wit...](#)

[Table 25.2 Potential mechanisms linking diabetes and cancer.](#)

Chapter 27

[Table 27.1 Relative risks \(95% CI\) for type 2 diabetes in people with serious...](#)

Chapter 28

[Table 28.1 Drugs that may exacerbate or provoke hyperglycaemia.](#)

Chapter 29

[Table 29.1 Diagnostic values of plasma glucose for Gestational Diabetes follo...](#)

[Table 29.2 Recommended blood glucose targets pre- and during pregnancy for bo...](#)

Chapter 30

[Table 30.1 Symptoms before diagnosis in 1260 children with type 1 diabetes.](#)

[Table 30.2 Clinical features of hypoglycaemia in children.](#)

Chapter 32

[Table 32.1 Recommendations for safe driving in people with diabetes taking in...](#)

Chapter 33

[Table 33.1 National Institute of Clinical Excellence \(NICE\) for diabetes in A...](#)

[Table 33.2 Pillars of integration.](#)

[Table 33.3 The 9 Key Care process. Every person with diabetes is supposed to ...](#)

Chapter 34

[Table 34.1 Types of stem cell and their relative advantages and disadvantages...](#)

List of Illustrations

Chapter 1

[Figure 1.1 Estimated comparative raw prevalence of diabetes and impaired glu...](#)

[Figure 1.2 Rates of major complications of diabetes for the US population de...](#)

[Figure 1.3 Age standardised mortality rates from diabetes-related complicati...](#)

[Figure 1.4 Estimated global diabetes-related healthcare costs for adults age...](#)

Chapter 2

[Figure 2.1 The Ebers papyrus. The Wellcome Institute Library, London, UK.](#)

[Figure 2.2 Thomas Willis. The Wellcome Institute Library, London, UK.](#)

[Figure 2.3 Claude Bernard. The Wellcome Institute Library, London, UK.](#)

[Figure 2.4 Paul Langerhans. The Wellcome Institute Library, London, UK.](#)

[Figure 2.5 Charles Best and Frederick Banting in Toronto in 1922 \(the dog is...](#)

[Figure 2.6 Schematic amino acid sequence of human insulin; porcine and bovin...](#)

Chapter 3

[Figure 3.1 Prevalence of diabetes-specific retinopathy \(moderate or more sev...](#)

[Figure 3.2 The relationship between 2-hour plasma glucose and survival in pa...](#)

[Figure 3.3 *Diagnosis of diabetes and IGT by the oral glucose tolerance test....*](#)

[Figure 3.4 *The prevalence of retinopathy in type 2 diabetes relative to the ...*](#)

[Figure 3.5 *High-risk patients who should be screened annually for type 2 dia...*](#)

[Figure 3.6 *Classification of diabetes.*](#)

[Figure 3.7 Using C-peptide to confirm type 1 diabetes based on residual beta...](#)

[Figure 3.8 Five replicable clusters of patients with diabetes.](#)

[Figure 3.9 Clinical features of type 1 and type 2 diabetes.](#)

[Figure 3.10 Other specific types of diabetes.](#)

Chapter 4

[Figure 4.1 Rising numbers of people with diabetes worldwide. IDF Atlas, 2017...](#)

[Figure 4.2 There are estimated to be 425 m patients with diabetes worldwide ...](#)

[Figure 4.3 An alarming trend in the USA with increasing numbers of patients....](#)

[Figure 4.4 Mortality rates due to diabetes-related complications. IDF Atlas,...](#)

[Figure 4.5 Premature mortality affects low-, medium- and high-income countri...](#)

[Figure 4.6 The relationship between Body Mass Index and the hazard ratio for...](#)

[Figure 4.7 Healthcare expenditure on diabetes is rising steeply. IDF Atlas,...](#)

[Figure 4.8 In the USA the costs of providing diabetes care are enormous. Bas...](#)

[Figure 4.9 Factors affecting the numbers of patients with type 2 diabetes.](#)

[Figure 4.10 The shift towards using new, expensive analogue insulins. IMS He...](#)

[Figure 4.11 A structured lifestyle modification program \(aimed at delivering...](#)

Chapter 5

[Figure 5.1 A section of normal pancreas stained with haematoxylin and eosin....](#)

[Figure 5.2 The localisation of pancreatic hormones in human islets. \(a\) Insu...](#)

[Figure 5.3 Potential interactions between the secretory products of the majo...](#)

[Figure 5.4 Structure of a pancreatic islet, showing the anatomical relations...](#)

[Figure 5.5 A hypothetical model for postnatal pancreatic \$\beta\$ cell growth in hu...](#)

[Figure 5.6 The primary structure \(amino acid sequence\) of human insulin. The...](#)

[Figure 5.7 The double zinc insulin hexamer composed of three insulin dimers ...](#)

[Figure 5.8 Insulin biosynthesis and processing. Proinsulin is cleaved on the...](#)

[Figure 5.9 \(a\) Electron micrograph of insulin secretory granules in a pancre...](#)

[Figure 5.10 The regulated \(normal\) and constitutive \(active in type 2 diabet...](#)

[Figure 5.11 \(a\) The biphasic glucose-stimulated release of insulin from panc...](#)

[Figure 5.12 The mechanism of glucose-stimulated insulin secretion from the \$\beta\$...](#)

[Figure 5.13 The classic experiment illustrating the incretin effect in norma...](#)

[Figure 5.14 \(a\) The incretin effect is greatly diminished in patients with t...](#)

[Figure 5.15 The insulin receptor and its structural domains. Many mutations ...](#)

[Figure 5.16 The insulin signalling cascade. Insulin binding and autophosphor...](#)

[Figure 5.17 \(a\) The structure of a typical glucose transporter \(GLUT\). \(b\) T...](#)

[Figure 5.18 Insulin regulation of glucose transport into cells.](#)

[Figure 5.19 Profiles of plasma glucose and insulin concentrations in individ...](#)

[Figure 5.20 Overview of carbohydrate metabolism. cats, catecholamines; cort,...](#)

Chapter 6

[Figure 6.1 Age and sex standardised incidence rates per 100,000 population p...](#)

[Figure 6.2 Incidence rates \(1999-2003\) of type 1 diabetes in 0-14-year-olds ...](#)

[Figure 6.3 Seasonal variation of type 1 diabetes among Finnish children \(a\) ...](#)

[Figure 6.4 Insulitis. There is a chronic inflammatory cell infiltrate centre...](#)

[Figure 6.5 ICA demonstrated by indirect immunofluorescence in a frozen secti...](#)

[Figure 6.6 Progression to symptomatic Type 1 Diabetes in 585 children with t...](#)

[Figure 6.7 Potential mechanisms of viral aetiology of autoimmune and non-aut...](#)

[Figure 6.8 Proposed mechanisms of \$\beta\$ cell death. \$\beta\$ cells die through a proces...](#)

[Figure 6.9 Stages of Type 1 Diabetes as proposed by the Juvenile Diabetes Re...](#)

[Figure 6.10 Lifetime risk of developing Type 1 diabetes \(left axis\) compared...](#)

Chapter 7

[Figure 7.1 The relationship between body mass index \(BMI\) and risk of type 2...](#)

[Figure 7.2 Rising obesity rates in the USA \(2008-2015\) based on self-report...](#)

[Figure 7.3 The rising Prevalence of type 2 diabetes parallels the rising inc...](#)

[Figure 7.4 Age-adjusted prevalence rates of type 2 diabetes in different geo...](#)

[Figure 7.5 The IDF atlas also monitors the rising prevalence of prediabetes ...](#)

[Figure 7.6 A league table of countries showing widely different prevalence r...](#)

[Figure 7.7 Deaths attributable to diabetes are highest in low- and middle-in...](#)

[Figure 7.8 The relationship between HbA1c and the incidence of cardiovascula...](#)

[Figure 7.9 Varying prevalence rates of type 2 diabetes by ethnicity/region a...](#)

[Figure 7.10 Weight gain is a particularly strong driver of type 2 diabetes r...](#)

[Figure 7.11 Insulin resistance \(as assessed by glucose infusion rate \(GIR\) t...](#)

[Figure 7.12 Age-adjusted risk of type 2 diabetes among 5990 men. The figure ...](#)

[Figure 7.13 The natural history of type 2 diabetes development often begins ...](#)

[Figure 7.14 Mechanisms of insulin resistance in type 2 diabetes.](#)

[Figure 7.15 The 'thrifty phenotype' hypothesis.](#)

[Figure 7.16 \$\beta\$ -cell function as measured by the homeostasis model assessment ...](#)

[Figure 7.17 Plasma concentrations of glucose and insulin in subjects with ty...](#)

[Figure 7.18 The stages of glucose tolerance and associated \$\beta\$ cell function a...](#)

[Figure 7.19 Pathogenesis of type 2 diabetes. Both genetic and environmental ...](#)

Chapter 8

[Figure 8.1 Rabson-Mendenhall syndrome in a 12-year-old boy, showing growth r...](#)

[Figure 8.2 Acanthosis nigricans on the nape of the neck of a 26-year-old wom...](#)

[Figure 8.3 Optic atrophy \(note white optic disc\) in a patient with Wolfram's...](#)

[Figure 8.4 Acute pancreatitis. CT scan of the abdomen, showing marked oedema...](#)

[Figure 8.5 Pancreatic calculi, showing characteristic patterns in alcoholic ...](#)

[Figure 8.6 A patient with glucagonoma, showing characteristic necrolytic mig...](#)

Chapter 9

[Figure 9.1 Correlation in patients with type 1 diabetes between blood glucos...](#)

[Figure 9.2 Example of combined blood glucose and blood ketone meter together...](#)

[Figure 9.3 Urine ketone testing strips. NOTE these detect urinary acetoaceta...](#)

[Figure 9.4 Continuous Glucose Sensor and Transmitter and associated Meter. T...](#)

[Figure 9.5 Flash \(intermittent\) glucose monitoring system. Sensor and transm...](#)

[Figure 9.6 Clarke error grid showing the density of paired FreeStyle Navigat...](#)

[Figure 9.7 Computer download of 14 days' data from continuous glucose monito...](#)

[Figure 9.8 Computer download of 14 days' data from flash monitoring device i...](#)

[Figure 9.9 CGM Target Ranges for different groups of patients as agreed by i...](#)

Chapter 10

[Figure 10.1 Normal plasma glucose and insulin profiles. Shaded areas represe...](#)

[Figure 10.2 Basal-bolus insulin regimen.](#)

[Figure 10.3 Schematic amino acid sequence of native human insulin; porcine a...](#)

[Figure 10.4 What happens in the subcutaneous tissue after subcutaneous injec...](#)

[Figure 10.5 Suitable sites for subcutaneous insulin injection.](#)

[Figure 10.6 Suprapubic lipohypertrophy at habitually used insulin injection s...](#)

[Figure 10.7 Example of disassembled insulin pen. Insulin dose is selected us...](#)

[Figure 10.8 Insulin infusion pump, fillable insulin cartridge \(left\), subcut...](#)

[Figure 10.9 Insulin infusion pump and glucose sensor fitted on a patient wit...](#)

[Figure 10.10 Meta regression analysis of mean effect size of insulin pump th...](#)

Chapter 11

[FIGURE 11.1 Management of type 2 diabetes: the initial measures.](#)

[FIGURE 11.2 Change in weight during energy restriction is similar with high ...](#)

[FIGURE 11.3 Effect of Orlistat in obese patients with type 2 diabetic.](#)

[Figure 11.4 Effect of Mysimba in obese patients with type 2 diabetes.](#)

[FIGURE 11.5 Practical food recommendations for patients with diabetes.](#)

[FIGURE 11.6 The progressive rise in median HbA1c with time in the convention...](#)

[Figure 11.7 Pharmacologic Approaches to Glycemic Treatment in type 2 diabete...](#)

[Figure 11.8 Approach to individualising Hba1c target in people with type 2....](#)

[Figure 11.9 Mechanism by which glucose and sulfonylureas stimulate insulin s...](#)

[Figure 11.10 Mechanism of action of TZDs. These agents stimulate the peroxis...](#)

[Figure 11.11 Mechanism of action of SGLT- 2 inhibitor.](#)

[Figure 11.12 LEADER STUDY. \(available free online from <https://tracs.unc.edu...>](#)

[Figure 11.13 Summary of glucose lowering therapy in type 2 diabetes.](#)

[Figure 11.14 **\(a\)** Different types of common bariatric surgery procedures **\(b\)** t...](#)

Chapter 12

[Figure 12.1 \(a\) Age distribution of 746 episodes of diabetic ketacidosis \(ex...](#)

[Figure 12.2 Mechanisms of ketacidosis. NEFA, non-esterified fatty acids.](#)

[Figure 12.3 Flowchart for the investigation of diabetic ketoacidosis.](#)

[Figure 12.4 Guide to the initial treatment of diabetic ketacidosis in adults...](#)

Chapter 13

[Figure 13.1 Some consequences of hypoglycaemia in diabetes.](#)

[Figure 13.2 Major components of the counter-regulatory and sympathetic nervo...](#)

[Figure 13.3 Glycemic thresholds for secretion of counterregulatory hormones ...](#)

[Figure 13.4 In the Diabetes Control and Complications Trial \(DCCT, a landmar...](#)

[Figure 13.5 Risks of severe hypoglycaemia associated with different diabetes...](#)

[Figure 13.6 Glycaemic thresholds for the release of epinephrine and activati...](#)

[Figure 13.7 Impairment of counter-regulatory responses in type 1 diabetes. \(...\)](#)

[Figure 13.8 The vicious circle of repeated hypoglycaemia.](#)

[Figure 13.9 Proposed mechanism of linking hypoglycaemia and arrhythmias in p...](#)

[Figure 13.10 Algorithm for treating acute hypoglycaemia in patients with dia...](#)

Chapter 14

[Figure 14.1 Schematic showing interaction of haemodynamic and cellular facto...](#)

[Figure 14.2 Prevalence of diabetic neuropathy as a function of duration of d...](#)

[Figure 14.3 Progression of proliferative retinopathy is related to glycated ...](#)

[Figure 14.4 Effect of intensive treatment on the onset of retinopathy. Cumul...](#)

[Figure 14.5 Risk of retinopathy progression and mean glycated haemoglobin in...](#)

[Figure 14.6 Effect of intensive blood glucose control on microvascular compl...](#)

[Figure 14.7 The relationship between glycated haemoglobin percentage and car...](#)

[Figure 14.8 Kaplan-Meier plots of proportions of patients who developed micr...](#)

[Figure 14.9 Cumulative incidence of a three-step change in ETDRS retinopathy...](#)

[Figure 14.10 The polyol pathway. \(*Left*\) The pathway is normally inactive, bu...](#)

[Figure 14.11 Formation of reversible, early, non-enzymatic glycation product...](#)

[Figure 14.12 Possible mechanisms of cell damage by interactions of advanced ...](#)

[Figure 14.13 Activation of protein kinase C by *de novo* synthesis of diacylg...](#)

[Figure 14.14 The hexosamine pathway. Glucosamine-6-phosphate, generated from...](#)

[Figure 14.15 Superoxide links glucose and diabetic complications.](#)

Chapter 15

[Figure 15.1 Structure of the retinal microvasculature. The endothelial cells...](#)

[Figure 15.2 Microaneurysms, the earliest sign of diabetic retinopathy appear...](#)

[Figure 15.3 Fluorescein angiogram, showing microaneurysms as small white dot...](#)

[Figure 15.4 Retinal haemorrhages: red 'blots'.](#)

[Figure 15.5 Focal diabetic maculopathy with circinate \(ring-shaped\) exudate....](#)

[Figure 15.6 Cotton wool spots around the optic disc. Note also flame and blo...](#)

[Figure 15.7 Intraretinal microvascular abnormalities \(IRMAs\) appearing as a ...](#)

[Figure 15.8 Venous irregularity or 'beading' \(centre of field\) and new vesse...](#)

[Figure 15.9 More extensive new vessels on the disc, occupying more than half...](#)

[Figure 15.10 Extensive neovascularisation above the disc, with widespread si...](#)

[Figure 15.11 Preretinal haemorrhage. Note the settling of the uncoagulated b...](#)

[Figure 15.12 Fibrous bands that are exerting traction on the retina. The ret...](#)

[Figure 15.13 Rhegmatogenous retinal detachment: a large retinal tear \(red le...](#)

[Figure 15.14 B-scan ultrasound image of the eye, showing a retinal detachmen...](#)

[Figure 15.15 Diffuse macular oedema, with a macular 'star'. This requires la...](#)

[Figure 15.16 Left eye of a patient with diffuse diabetic macular oedema. \(a\)...](#)

[Figure 15.17 New vessels \(arrows\) on the iris \(rubeosis iridis\). There is al...](#)

[Figure 15.18 Diabetic cataract appearing as pale opacification of the lens....](#)

[Figure 15.19 Recent panretinal \(scatter\) laser photocoagulation burns for tr...](#)

[Figure 15.20 Focal laser photocoagulation scars around the macula following...](#)

Chapter 16

[Figure 16.1 Classification and prognosis for end stage renal disease based u...](#)

[Figure 16.2 Hyperfiltration in diabetes and its correction by SGLT-2 \(sodium...](#)

[Figure 16.3 Relative mortality of patients with diabetes with and without pe...](#)

[Figure 16.4 Nodular glomerulosclerosis in a patient with type 1 diabetes and...](#)

[Figure 16.5 Nodular glomerulosclerosis \(Kimmelstiel-Wilson lesions\) in a pat...](#)

[Figure 16.6 Electron micrograph of the glomerulus from a patient with diabet...](#)

[Figure 16.7 Schematic to show how metabolic and haemodynamic factors combine...](#)

[Figure 16.8 Schematic of changes in selectivity of glomerular capillary to a...](#)

[Figure 16.9 Prevalence of parental hypertension in type 1 patients with norm...](#)

[Figure 16.10 \(a\) Prevalence and \(b\) cumulative incidence of moderate albumin...](#)

[Figure 16.11 Effects of antihypertensive treatment on \(a\) mean arterial bloo...](#)

[Figure 16.12 Meta-analysis of the effects of angiotensin-converting enzyme \(...\)](#)

[Figure 16.13 \(a\) Cumulative incidence of death in 160 moderately albuminuric...](#)

[Figure 16.14 Frequency of monitoring \(number of clinic visits per year\) base...](#)

[Figure 16.15 Reciprocal serum creatinine plotted against date for the case h...](#)

[Figure 17.1 Diabetic neuropathy is common and associated with a complex mix ...](#)

[Figure 17.2 Classification of diabetic neuropathy.](#)

[Figure 17.3 Mechanisms of diabetic neuropathy.](#)

[Figure 17.4 Clinical pattern of distal symmetrical neuropathies.](#)

[Figure 17.5 Staging the severity of diabetic neuropathy.](#)

[Figure 17.6 Positive sensory symptoms; painful neuropathy.](#)

[Figure 17.7 A 10g monofilament is simple, easy to use in the clinic and is m...](#)

[Figure 17.8 Increased blood flow \(distended veins\) on the dorsum of the foot...](#)

[Figure 17.9 Clinical pattern of pressure palsies in patients with diabetes....](#)

[Figure 17.10 Generalised wasting of the interossei \(and hypothenar eminence\)...](#)

[Figure 17.11 Diabetic amyotrophy, showing marked quadriceps wasting, and cli...](#)

[Figure 17.12 Histological changes associated with diabetic amyotrophy. In pa...](#)

[Figure 17.13 Clinical and subclinical features of diabetic autonomic neuropa...](#)

[Figure 17.14 Effects of intensified insulin therapy and strict glycaemic con...](#)

Chapter 18

[Figure 18.1 Features of Diabetic dyslipidaemia. In the German PROCAM study, ...](#)

[Figure 18.2 The pathogenesis of diabetic dyslipidaemia involves increased re...](#)

[Figure 18.3 Eruptive xanthomata. This young patient with type 1 diabetes pre...](#)

[Figure 18.4 The MRFIT screening study enrolled >360,000 men in the 1960s-70s...](#)

[Figure 18.5 The importance of LDL cholesterol lowering to reduce major vascu...](#)

[Figure 18.6 Circulating cholesterol is derived from two sources: de novo syn...](#)

[Figure 18.7 A meta-analysis of cholesterol-lowering therapy in 18 686 patien...](#)

[Figure 18.8 The mechanism of action of statins and PCSK9 monoclonal antibodi...](#)

Chapter 19

[Figure 19.1 Suggested mechanisms linking insulin resistance to the developme...](#)

[Figure 19.2 Additive effects of diabetes and hypertension on deaths from cor...](#)

[Figure 19.3 World Health Organisation/International Society for Hypertension...](#)

[Figure 19.4 Schematic diagram of the renin-angiotensin system. Dotted lines ...](#)

[Figure 19.5 Summary of antihypertensive drug management in people with diabe...](#)

Chapter 20

[Figure 20.1 Relationships between systolic BP \(a\) and serum cholesterol \(b\) ...](#)

[Figure 20.2 Among patients with diabetes, those who develop nephropathy and ...](#)

[Figure 20.3 Arteriolar changes in diabetes in the myocardium of a woman who ...](#)

[Figure 20.4 Medial calcification of the digital arteries in a diabetic patie...](#)

[Figure 20.5 New Zealand cohort study showing the relationship between CVD mo...](#)

[Figure 20.6 DAG-mediated activation of protein Kinase C- \$\beta\$ results in phospho...](#)

[Figure 20.7 Advanced glycation end products \(AGEs\) have a number of unwanted...](#)

[Figure 20.8 A meta-analysis of five prospective randomised controlled trials...](#)

[Figure 20.9 Cardiovascular and death from any course with Empagliflozin comp...](#)

[Figure 20.10 Primary and exploratory outcomes with Liraglutide vs Placebo in...](#)

[Figure 20.11 The ADVANCE study randomised approximately 20,000 high-risk pat...](#)

[Figure 20.12 Age-adjusted prevalence of previous stroke among type 2 diabete...](#)

[Figure 20.13 From the Antithrombotic Trialists Collaboration, there is no cl...](#)

[Figure 20.14 Age-adjusted prevalence of intermittent claudication in patient...](#)

[Figure 20.15 Diffuse coronary artery disease in a 49-year-old woman with typ...](#)

[Figure 21.1 The 'diabetic foot' refers to a mix of pathologies.](#)

[Figure 21.2 Major components in the aetiology of foot ulceration.](#)

[Figure 21.3 Risk factors for diabetic foot complications.](#)

[Figure 21.4 Annual foot review for everyone with diabetes above 12 years old...](#)

[Figure 21.5 Typical neuropathic ulcer with surrounding callus.](#)

[Figure 21.6 *Neuroischaemic damage caused by tightly fitting shoes.*](#)

[Figure 21.7 Principles of ulcer treatment, in addition to providing educatio...](#)

[Figure 21.8 Critical ischaemia, ulceration and gangrene affecting the extrem...](#)

[Figure 21.9 Bilateral Charcot neuroarthropathy in the cuneiform-metatarsal a...](#)

[Figure 21.10 Plain X-ray of a Charcot foot demonstrates gross destruction, d...](#)

[Figure 21.11 Total contact plaster cast for 'offloading' a neuropathic ulcer...](#)

[Figure 21.12 The following clinical scenario and anti-microbial agents that ...](#)

Chapter 22

[Figure 22.1 The most common symptoms of sexual dysfunction in men and women ...](#)

[Figure 22.2 Sexual Health Inventory for Men \(SHIM\).](#)